Cost-effectiveness of blood-based colorectal cancer screening – a simulation model incorporating real-world longitudinal adherence
The CAN-SCREEN model shows that Shield is cost-effective compared to no screening. Including real-world adherence improves accuracy in assessing screening strategies. Shield's noninvasive approach offers a promising, cost-effective way to increase adherence and reduce CRC mortality.
Authors
- Elifnur Yay Donderici
- Shaun P. Forbes (ORCID: https://orcid.org/0000-0002-4026-1817)
- Amar K. Das (ORCID: https://orcid.org/0000-0003-3556-0844)
- AmirAli Talasaz (ORCID: https://orcid.org/0000-0002-2944-6458)
- William M. Grady (ORCID: https://orcid.org/0000-0002-0129-7809)
- Nicole Zhang (ORCID: https://orcid.org/0009-0001-2706-5838)
- Victoria M. Raymond (ORCID: https://orcid.org/0000-0001-5223-0981)
- Craig Eagle
- Gregory Schafer
Institutions
- University of Washington (US)
- Fred Hutch Cancer Center (US)
- Guardant (United States) (US)
Publication Details
- Journal
- Expert Review of Pharmacoeconomics & Outcomes Research
- Published
- 2025-02-03
- DOI
- https://doi.org/10.1080/14737167.2025.2458044
- Citations
- 4
- Primary Topic
- Colorectal Cancer Screening and Detection
- Type
- article
- Field-Weighted Citation Impact
- 4.18